BIORCHESTRA, a biotech startup headquartered in Daejeon, South Korea, has appointed Dr. Gabriel Helmlinger (Ph.D., D.A.B.T.) as Vice-President, Head of Translational & Clinical Pharmacology, Toxicology.

Dr Helmlinger brings 25 years of drug research and clinical development experience in the biotech and global pharmaceutical industries. Prior to joining BIORCHESTRA, he managed organizations and programs of drug development, translational & clinical pharmacology, toxicology, biomarkers, and quantitative data analytics at Novartis (2001-2014), AstraZeneca (2014-2020), and Obsidian Therapeutics, a gene & cell therapy biotech (2020-2022). 

He brings extensive expertise in the nonclinical, translational and clinical assessment of novel therapeutic candidates and in the focused areas of pharmacology, biomarker identification, drug delivery systems, study design, diagnostics, over a wide range of disease domains and therapeutic modalities. He has also contributed to multiple regulatory submissions and agency interactions. Dr Helmlinger has additional broad experience in the translational pharmacology of small molecules, peptides, antibodies and antibody-based constructs, gene and cell therapies, as well as various molecular and micromechanical delivery systems.